> >Register Now <<

Speaker: Lindsay Oberman, PhD

This talk will review the Pro’s and Cons of off-label use of TMS. Dr. Oberman will then discuss the FDA clearance process and what indications are considered “off-label”. Finally, she will discuss the legal and ethical considerations for marketing and promoting off-label uses of TMS.

Key learning objectives include:

• Gain awareness of what indications are "on label" versus "off label."
• Gain awareness of federal regulations regarding marketing and promotion of FDA cleared devices.
• Gain understanding of ethical considerations regarding marketing and use of rTMS off-label.

One CME credit is available.  CE Language

Take advantage of our live Q&A session at the conclusion of the webinar.

*Registered attendees will receive access to the on-demand video recording by Friday, April 10, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.

When:

USA - April 7, 2026 at 8:00pm ET | 5:00pm PT
UK- April 8, 2026 at 1:00am BST
Australia- April 8, 2026 at 10:00am AEST

Cost:

Member: $25
Trainee Member: FREE
Non-Member: $50

> >Register Now <<

About the Speaker

Lindsay Oberman, PhD
Dr. Lindsay Oberman received her PhD from UCSD in Experimental Psychology in 2007. Since that time, she has published over 80 peer-reviewed articles. She has gained international attention for pioneering the use of Repetitive Transcranial Magnetic Stimulation (rTMS) in complex neurodevelopmental and neuropsychiatric disorders including autism, mood disorders, and traumatic brain injury. Dr. Oberman’s research involves the use of an experimental therapeutics approach applying neuroimaging and neurophysiological measures to identify dysfunctional neural circuitry associated with specific transdiagnostic behavioral domains such as mood regulation, sensory processing, social cognition, and executive functioning across disorders. In doing so, she is able to develop novel individualized rTMS treatment protocols that are informed by functional brain network organization. She is currently a Staff Scientist and Directs the Developmental Clinical Neurophysiology and Neurostimulation Research Program within the National Institute of Mental Health Intramural Research Program.